Post-Vaccinial Encephalitis Diagnostic and Management None for specific diagnosis of PVE Diagnosis of exclusion – Consider other infectious or toxic etiologies.

Slides:



Advertisements
Similar presentations
Hospital Issues and Smallpox Vaccine Lisa G. Kaplowitz, M.D., M.S.H.A. Deputy Commissioner Emergency Preparedness and Response Virginia Department of Health.
Advertisements

Common dilemmas in Pregnancy Andy Lindop. Chickenpox Can cause problems for Mum to be and her unborn Can cause problems for Mum to be and her unborn Incidence.
Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.
Vaccinia Immune Globulin and Cidofovir Centers for Disease Control and Prevention Department of Health and Human Services Smallpox Vaccine Adverse Event.
DMC HVSH Guidelines for Suspected Smallpox Vaccine Adverse Events Evaluation Confirm that individual is smallpox vaccinee (should have PVN card) Those.
Rash Illness Evaluation
IMMUNIZATION Immunization??? Reduce mortality and morbidity of mathernal and baby.
Current expectations for laboratory testing and adverse smallpox vaccine reactions Department of Health and Human Services Centers for Disease Control.
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
Management of Smallpox Vaccine Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention February 2003.
Site Care. Site Care Education Goals Review normal reactions after vaccination Provide site care instructions (oral and written) Provide contact information.
Perinatal Varicella By Rafat Mosalli MD FAAP FRCPC.
Case scenario 3 Clinical Breakout Session Smallpox Vaccine Adverse Event Workshop January 22-23, 2003.
Back to the Future? Pre-Event Smallpox Vaccination John R. Lumpkin, MD, MPH, FACEP Illinois Department of Public Health.
Special Topics in IND Regulation
Adult Immunization 2010 Influenza Segment This material is in the public domain This information is valid as of May 25, 2010.
Smallpox Vaccine Contraindications and Screening Department of Health and Human Services Centers for Disease Control and Prevention December 2002 Note:
Adult Immunization 2010 Herpes Zoster (Shingles) Segment This material is in the public domain This information is valid as of May 25, 2010.
Varicella Zoster Virus Herpesvirus (DNA) Primary infection results in varicella (chickenpox) Recurrent infection results in herpes zoster (shingles) Short.
Chickenpox (varicella)
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases Centers.
Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.
Adult Immunization 2010 Tetanus, Diphtheria and Pertussis Segment This material is in the public domain This information is valid as of May 25, 2010.
Herpes Zoster Vaccination Anupama Raghuram, MD Assistant Professor Department of Internal Medicine Division of Infectious Diseases August 7 th, 2013.
Rapivab™ - peramivir injection
Presented by Dr. Lisa Rotz, BPRP, CDC.
National Smallpox Vaccination Update Joseph M. Henderson Centers for Disease Control and Prevention.
Smallpox Vaccination: Federal Activities Walter A. Orenstein, M.D. National Immunization Program Centers for Disease Control and Prevention.
Page Up to Reverse  Employee Health  Page Down to Advance  Employee Health 
Immunization م. م زيد وحيد عاجل. Immunity : The ability to destroy a particular antigen, it is may be inherited (natural) or acquired (artificial). Natural.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention February 2003.
Smallpox By Amber, Jacob, And Olivia. Smallpox is a serious and contagious disease that causes a rash on the skin.
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
1 DoD Smallpox Vaccination Program Policy – Training – Standards – Communication – Safety Assurance – Safety Assessment Science – Quality – Confidence.
38 th National Immunization Conference May 14, 2004 Smallpox Vaccine Adverse Events Revisited. What have we learned? John Neff MD Seattle,Washington.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Approved: 9 Jun DoD Leader’s Briefing: Force Health Protection Against Anthrax.
EPI VACCINES. BCG ( Bacille Calmette- Guerin)  Protects infants against TB  In powder form with diluents  Must be discarded after 6 hrs. or at the.
Smallpox Vaccination Mark Upfal, MD, MPH Detroit Medical Center Emergency Medicine Grand Rounds Detroit Receiving Hospital February 13, 2003 Collaborators:
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
DoD Smallpox Vaccination Program Science – Quality – Confidence – Care 3 June 2003 COL John D. Grabenstein, RPh, PhD Military Vaccine (MILVAX) Agency U.S.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
Division of Hematology Emergency Preparedness Action Initiatives Prepared by Mark Weinstein, Ph.D., Dorothy Scott M.D. and Basil Golding M.D. Division.
Chickenpox in Pregnancy Max Brinsmead MB BS PhD January 2015.
BCG Vaccine Usual reactions induration: 2 – 4 wks pustule formation: 5 – 7 wks scar formation: 2 – 3 months Accelerated Reactions: induration: 2-3 days.
What are the health benefits and risks associated with vaccinating your child and why is it so important ?
CHAPTER 46 Immunizing Drugs and Biochemical Terrorism 1/7/20161Winter 2013.
Varicella and Varicella Vaccine
Dr. Athal Humo transient Passive immunity is achieved by administration of preformed antibodies to induce transient protection against an infectious.
1 Influenza Vaccination 2016 Cluster: Communicable Disease, NDoH.
Exit Review Area  Objective Understand Your Role in the Exit Review Area Understand Your Role in the Exit Review Area.
Prepared by the AETC National Coordinating Resource Center based on recommendations from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious.
Management infant born with mother Chickenpox
Vaccination د.رائد كريم العكيلي.
Infection Control Q and A APIC Greater NY Chapter 13 May 17, 2017 Beth Nivin BA MPH NYC DOHMH Communicable Disease Program
Eucrisa™ - Crisaborole
Foundations of Interprofessional Collaboration (FIPC): An Introduction to TeamSTEPPS® LEVEL 3 Overview of Clinical Management of Anaphylaxis for Respiratory.
Human Varicella-Zoster Immune Globulin
Vesicular Rash Presented by: Dr.Abeer omran
This is an archived document.
                       What is a Rash?.
Criteria for admission of rash diseases to High-Security Care
Diagnosed Food Handlers
Immunization Update 2007 Varicella Vaccine Segment
Smallpox Vaccine Contraindications and Screening
Smallpox Vaccinee Evaluation and Follow-Up
Presentation transcript:

Post-Vaccinial Encephalitis Diagnostic and Management None for specific diagnosis of PVE Diagnosis of exclusion – Consider other infectious or toxic etiologies 15-25% mortality rate 25% varying neurological deficits VIG not recommended

Fetal Vaccinia

Associating the Condition with the Vaccine Know Chronology of immunization and adverse event Corresponds to those previously associated Biologic plausibility Lab result confirms association Recurs on re-administration Controlled clinical or epi trial shows association

Revaccination of Those with History of AE In absence of smallpox, do NOT revaccinate Defer those not vaccinated from response teams

Prophlyaxis of High-Risk Groups Accidentally Exposed VIG NOT recommended Vigilant clinical follow-up Do NOT administer VIG with smallpox vaccine Exclude those with contraindications

Laboratory Diagnosis

Laboratory Diagnosis Rule Out Testing Varicella Herpes Zoster Herpes Simplex Enteroviruses

Laboratory Diagnosis Tests Available Electron Microscopy (EM) - Orthopoxvirus PCR – Gene Amplification Viral Culture – Identify vaccinia May be available through LRN Consult with CDC for testing advice

Specimen Collection Contact state health department CDC Interim Smallpox Response Plan, Guide D

Treatments

Vaccinia Immune Globulin Immunoglobulin fraction of plasma Antibodies to vaccinia from vaccinated donors Previously-licensed IM product (Baxter)  Contains 0.01% thimerosal New IV products in production Obtain as IND product through CDC and DoD

VIG Indications Indications Eczema vaccinatum Progressive vaccinia Vaccinia necrosum Generalized vaccinia – severe cases

Vaccinia Immune Globulin Indications Recommended Inadvertent Inoculation - severe Eczema vaccinatum Generalized vaccinia – severe or underlying illness Progressive vaccinia Not Recommended Inadvertent Inoculation – Not severe Generalized vaccinia – mild or limited Non-specific rashes, EM, SJS Post-vaccinial encephalitis Consider Ocular complications

Vaccinia Immune Globulin Side Effects - Mild Local Pain Tenderness Swelling Erythema From few hours to 1 or 2 days

Joint Pain Diarrhea Dizziness Hyperkinesis Drowsiness Pruritis Rash Perspiration Vasodilation Vaccinia Immune Globulin Side Effects - Moderate

Hypotension Anaphylaxis Renal Dysfunction Aseptic Meningitis Syndrome (AMS) Vaccinia Immune Globulin Side Effects - Serious

Vaccinia Immune Globulin Contraindications Allergic reaction to thimerosal History of severe reaction with IG preparations IgA Deficiency Vaccinia keratitis, except in some cases Pregnancy Theoretical risks as with all human plasma

VIG Administration VIG-IM 0.6ml/kg IM, preferably in buttock or anterolateral aspect of thigh Divide doses > 5ml Refer to package insert

Cidofovir Nucleotide analogue of cytosine Some antiviral activity against orthopoxviruses Administer under IND protocol, only Released by CDC and DoD if:  No response to VIG  Patient near death  All inventories of VIG exhausted

Cidofovir Side Effects Renal toxicity Neutropenia Proteinuria Decreased intraocular pressure Anterior uveitis/iritis Metabolic acidosis

Cidofovir Admin 5 mg/kg IV over 60 minute period Consider 2 nd dose one week later if no response Adjust dose for renal function Assess baseline and post-admin renal function IV hydration (1L of 0.9% saline IV) 3 doses oral probenicid (25 mg/kg per dose)

Obtaining VIG and Cidofovir Civilian Medical Facilities  CDC Smallpox Vaccinee Adverse Events Clinical Team Military Facilities  USAMRIID (301) or 888-USA-RIID

Consultation

State and Territories establish program Hospitals assign physicians with expertise Provide 24/7 access to vaccinees and affected contacts CDC Provider Information Line

Consultation Information to Have Thorough vaccination history Physical Examination of patient High-resolution digital photographs of dermatologic manifestations Contact state health department, first

Smallpox Adverse Event Reporting

VAERS Reporting Secure web-based reporting Downloadable form  Fax to:

Additional Information CDC Smallpox Website Adverse Events Training Module

Infection Control Documented rarely in healthcare settings Primarily after direct contact with site May occur with other infected body sites Indirect transmission possible, but never documented

Ocular Vaccinial Infections and Therapy

Treatment of Ocular Infections Previous experience with older antivirals Not done by today’s standards Currently available topical opthalmic antivirals not studied with vaccinia Animal studies

Animal studies, rabbit model of vaccinial keratitis Topical vidarabine or trifluridine Virologic and clinical improvement Early use might reduce complications Not approved by FDA for vaccinia disease Treatment of Ocular Infections Topical Opthalmic Anti-Virals

No evidence effective Might increase scarring after vaccinial keratitis Rabbit studies used increased doses Treatment of Ocular Infections Vaccinia Immune Globulin

Manage in consult with ophthalmologist Consider off-label use of topical ophthalmic trifluridine or vidarabine Balance with risk of drug toxicity Continue until periocular and/or lid lesions heal and scabs fall off Treatment of Ocular Infections Guidance for Clinicians

Consider VIG when keratitis NOT present Useful with severe blepharitis or blepharoconjunctivitis Weigh risks and benefits if keratitis present Use VIG for other severe vaccinia disease, even if keratitis present Consider prophylaxis against bacterial infection Enroll in studies Treatment of Ocular Infections Guidance for Clinicians